Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Shares Outstanding (Diluted Average) (2023 - 2025)

Goldenwell Biotech's Shares Outstanding (Diluted Average) history spans 3 years, with the latest figure at $96.4 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Diluted Average) changed 0.0% year-over-year to $96.4 million; the TTM value through Sep 2025 reached $96.4 million, changed 0.0%, while the annual FY2024 figure was $99.0 million, 0.0% changed from the prior year.
  • Shares Outstanding (Diluted Average) reached $96.4 million in Q3 2025 per GWLL's latest filing, roughly flat from $96.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $99.0 million in Q4 2023 to a low of $96.4 million in Q2 2024.
  • Average Shares Outstanding (Diluted Average) over 3 years is $97.7 million, with a median of $97.7 million recorded in 2023.
  • The largest YoY upside for Shares Outstanding (Diluted Average) was 0.0% in 2024 against a maximum downside of 0.0% in 2024.
  • A 3-year view of Shares Outstanding (Diluted Average) shows it stood at $99.0 million in 2023, then changed by 0.0% to $99.0 million in 2024, then dropped by 2.59% to $96.4 million in 2025.
  • Per Business Quant, the three most recent readings for GWLL's Shares Outstanding (Diluted Average) are $96.4 million (Q3 2025), $96.4 million (Q2 2025), and $99.0 million (Q1 2025).